Berkeley Capital Partners LLC lifted its holdings in Novartis AG (NYSE:NVS – Get Rating) by 34.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,844 shares of the company’s stock after purchasing an additional 981 shares during the period. Berkeley Capital Partners LLC’s holdings in Novartis were worth $336,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also made changes to their positions in the stock. Matthew Goff Investment Advisor LLC raised its position in shares of Novartis by 1.2% in the fourth quarter. Matthew Goff Investment Advisor LLC now owns 60,635 shares of the company’s stock valued at $5,304,000 after buying an additional 690 shares during the last quarter. MML Investors Services LLC lifted its stake in Novartis by 6.1% in the third quarter. MML Investors Services LLC now owns 69,800 shares of the company’s stock worth $5,708,000 after acquiring an additional 3,997 shares during the last quarter. First Fiduciary Investment Counsel Inc. raised its holdings in Novartis by 1.7% during the fourth quarter. First Fiduciary Investment Counsel Inc. now owns 170,223 shares of the company’s stock worth $14,889,000 after purchasing an additional 2,845 shares in the last quarter. FRG Family Wealth Advisors LLC acquired a new stake in Novartis during the fourth quarter worth approximately $899,000. Finally, Cambridge Investment Research Advisors Inc. increased its holdings in shares of Novartis by 8.3% in the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 54,346 shares of the company’s stock valued at $4,754,000 after acquiring an additional 4,162 shares during the period. Hedge funds and other institutional investors own 9.40% of the company’s stock.
Novartis stock traded down $0.64 during midday trading on Wednesday, reaching $91.29. The stock had a trading volume of 106,988 shares, compared to its average volume of 2,694,403. The company has a market capitalization of $204.19 billion, a P/E ratio of 8.56, a PEG ratio of 2.59 and a beta of 0.52. The company has a current ratio of 1.25, a quick ratio of 1.01 and a debt-to-equity ratio of 0.37. Novartis AG has a 12 month low of $79.09 and a 12 month high of $95.17. The company has a fifty day moving average price of $88.55 and a two-hundred day moving average price of $86.29.
Several equities research analysts have commented on NVS shares. Societe Generale decreased their target price on shares of Novartis from CHF 107 to CHF 105 in a research report on Thursday, February 3rd. Morgan Stanley raised their price objective on Novartis from CHF 90 to CHF 94 in a research note on Friday, May 6th. Barclays raised their price target on Novartis from CHF 80 to CHF 85 in a report on Thursday, April 14th. upgraded Novartis from a “hold” rating to a “buy” rating in a research report on Thursday, April 14th. Finally, Zacks Investment Research lowered Novartis from a “hold” rating to a “sell” rating and set a $94.00 price objective for the company. in a research report on Friday, April 22nd. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $90.50.
About Novartis (Get Rating)
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.
- Get a free copy of the StockNews.com research report on Novartis (NVS)
- Short-Covering Begins In Big Lots
- Agilent Technologies Is Bottoming But Don’t Buy It Yet
- Institutions Ring The Register On Toll Brothers Stock
- Dick’s Sporting Goods Falls Flat On Weak Guidance
- Two Retailers, One To Buy And One To Avoid
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.